Orphazyme A/S (ORPH)

submited by

Style Pass

2021-06-10 18:30:06

Pomerantz LLP is investigating claims on behalf of investors of Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

NEW YORK, NY / ACCESSWIRE / May 11, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orphazyme A/S ("Orphazyme" or "the Company") (NASDAQ:ORPH). Investors who purchased Orphazyme securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.

View more earnings on CRONSee more from BenzingaClick here for options trades from BenzingaAnalysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock PlungesOrphazyme Shares Plummet As Arimoclomol Flunks In Amyotrophic Lateral Sclerosis Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.